| Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation SG Holtan, TE DeFor, A Lazaryan, N Bejanyan, M Arora, CG Brunstein, ... Blood, The Journal of the American Society of Hematology 125 (8), 1333-1338, 2015 | 463 | 2015 |
| Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) RM Alvi, MJ Frigault, MG Fradley, MD Jain, SS Mahmood, M Awadalla, ... Journal of the American College of Cardiology 74 (25), 3099-3108, 2019 | 287 | 2019 |
| Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ... Haematologica 106 (4), 978, 2021 | 196 | 2021 |
| Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study C Cutler, SJ Lee, S Arai, M Rotta, B Zoghi, A Lazaryan, A Ramakrishnan, ... Blood, The Journal of the American Society of Hematology 138 (22), 2278-2289, 2021 | 193* | 2021 |
| High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma EA Dean, RS Mhaskar, H Lu, MS Mousa, GS Krivenko, A Lazaryan, ... Blood Advances 4 (14), 3268-3276, 2020 | 186 | 2020 |
| Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma MD Jain, H Zhao, X Wang, R Atkins, M Menges, K Reid, K Spitler, ... Blood, The Journal of the American Society of Hematology 137 (19), 2621-2633, 2021 | 181 | 2021 |
| Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American … T Jain, M Bar, AJ Kansagra, EA Chong, SK Hashmi, SS Neelapu, M Byrne, ... Biology of Blood and Marrow Transplantation 25 (12), 2305-2321, 2019 | 175 | 2019 |
| Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis C Casulo, JW Friedberg, KW Ahn, C Flowers, A DiGilio, SM Smith, ... Biology of blood and marrow transplantation 24 (6), 1163-1171, 2018 | 154 | 2018 |
| Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma AJ Sim, MD Jain, NB Figura, JC Chavez, BD Shah, F Khimani, A Lazaryan, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 1012-1021, 2019 | 143 | 2019 |
| ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease M Jagasia, A Lazaryan, CR Bachier, A Salhotra, DJ Weisdorf, B Zoghi, ... Journal of Clinical Oncology 39 (17), 1888-1898, 2021 | 115 | 2021 |
| Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD N Bejanyan, CG Brunstein, Q Cao, A Lazaryan, X Luo, J Curtsinger, ... Blood advances 2 (8), 909-922, 2018 | 102 | 2018 |
| Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors A Lazaryan, DJ Weisdorf, T DeFor, CG Brunstein, ML MacMillan, ... Biology of Blood and Marrow Transplantation 22 (1), 134-140, 2016 | 98 | 2016 |
| Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans A Lazaryan, E Lobashevsky, J Mulenga, E Karita, S Allen, J Tang, ... Journal of virology 80 (12), 6056-6060, 2006 | 87 | 2006 |
| Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia P Kebriaei, C Anasetti, MJ Zhang, HL Wang, I Aldoss, M de Lima, ... Biology of blood and marrow transplantation 24 (4), 726-733, 2018 | 84 | 2018 |
| Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 73 | 2022 |
| Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies V Bachanova, AE Frankel, Q Cao, D Lewis, B Grzywacz, MR Verneris, ... Clinical Cancer Research 21 (6), 1267-1272, 2015 | 70 | 2015 |
| Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel R Faramand, M Jain, V Staedtke, H Kotani, R Bai, K Reid, SB Lee, ... Clinical Cancer Research 26 (18), 4823-4831, 2020 | 63 | 2020 |
| Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma JM Logue, LC Peres, H Hashmi, CM Colin-Leitzinger, AM Shrewsbury, ... Blood Advances 6 (24), 6109-6119, 2022 | 54 | 2022 |
| Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors SG Holtan, N Khera, JE Levine, X Chai, B Storer, HD Liu, Y Inamoto, ... Blood, The Journal of the American Society of Hematology 128 (19), 2350-2358, 2016 | 53 | 2016 |
| Can G-CSF cause leukemia in hematopoietic stem cell donors? BR Avalos, A Lazaryan, EA Copelan Biology of Blood and Marrow Transplantation 17 (12), 1739-1746, 2011 | 53 | 2011 |